African Trypanosomiasis - Pipeline Review, H2 2016

Choose Licence

 

African Trypanosomiasis - Pipeline Review, H2 2016 Summary Global Markets Directs, African Trypanosomiasis - Pipeline Review, H2 2016?, provides an overview of the African Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis - The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects - The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 African Trypanosomiasis Overview 7 Therapeutics Development 8 Pipeline Products for African Trypanosomiasis - Overview 8 Pipeline Products for African Trypanosomiasis - Comparative Analysis 9 African Trypanosomiasis - Therapeutics under Development by Companies 10 African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 11 African Trypanosomiasis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 African Trypanosomiasis - Products under Development by Companies 15 African Trypanosomiasis - Products under Investigation by Universities/Institutes 16 African Trypanosomiasis - Companies Involved in Therapeutics Development 17 Novartis AG 17 Sanofi 18 Scynexis, Inc. 19 African Trypanosomiasis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 26 Drug Profiles 28 AN-5568 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 DDD-100097 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 fexinidazole - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 GNF-6702 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 melarsoprol hydroxypropylbetadex - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Peptides for Sleeping Sickness - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules for African Trypanosomiasis - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules for African Trypanosomiasis and Infectious Diseases - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules for Infectious Diseases - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules for Protozoal Infections - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules for Sleeping Sickness - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 African Trypanosomiasis - Dormant Projects 43 African Trypanosomiasis - Discontinued Products 44 African Trypanosomiasis - Product Development Milestones 45 Featured News & Press Releases 45 Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness 45 Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 45 Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49

List of Tables Number of Products under Development for African Trypanosomiasis, H2 2016 8 Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 African Trypanosomiasis - Pipeline by Novartis AG, H2 2016 17 African Trypanosomiasis - Pipeline by Sanofi, H2 2016 18 African Trypanosomiasis - Pipeline by Scynexis, Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 African Trypanosomiasis - Dormant Projects, H2 2016 43 African Trypanosomiasis - Discontinued Products, H2 2016 44


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports